medigraphic.com
ISSN 1684-1824 (Digital)

2016, Número 2

<< Anterior Siguiente >>

Rev Méd Electrón 2016; 38 (2)


Intervención genética en la cardiopatía isquémica temprana

Arredondo BA, Sifontes EMA, Arredondo RA

Idioma: Español
Referencias bibliográficas: 44
Paginas: 199-210
Archivo PDF: 351.88 Kb.


RESUMEN

Introducción: La aparición prematura de la enfermedad coronaria en una misma familia ha sido reconocida y se ha establecido como un factor de riesgo independiente de la enfermedad coronaria, se han demostrado cambios a corto plazo en la expresión genética en respuesta a la dieta, el ejercicio y el manejo del stress, produciendo cambios positivos a nivel molecular.
Materiales y métodos: Al haber encontrado evidencia de estudios que apoyan la hipótesis de que la aparición de la enfermedad coronaria prematura es un fuerte factor de riesgo se realizó una revisión utilizando las bases de datos: PubMed, Embase, MEDLINE y Scielo, donde se revisaron los artículos en Ingles y Castellano hasta comienzos del 2014.
Desarrollo: Los pacientes con historia parenteral de cardiopatía isquémica, presentaron una mortalidad más elevada a los 35 años, la implicación más importante es el riesgo sostenido de la enfermedad coronaria prematura, la cual comienza mucho antes de que los otros procesos patológicos se conviertan en factores de riesgo tradicionales, se identifiquen y traten, han sido demostrados cambios genéticos y moleculares asociados a mejoría del estado vascular, además existen enzimas capaces de modificar la actuación y eliminación de los medicamentos.
Conclusiones: La identificación de un evento coronario en una persona menor de 60 años debe indicar la necesidad urgente de una intervención activa en sus niños, buscando cambios dietéticos, de ejercicios físicos, e intervenciones sobre la tensión arterial, que debe ser continuada y sostenida para reducir factores de riesgo y obtener una mejor adhesión a los medicamentos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. 1-Moran AE, Roth GA, Narula J, Mensah GA. 1990-2010 global cardiovascular disease atlas. Global Heart [Internet]. 2014 [citado 12 May 2015];9(1):3-16.Disponible en: http://www.researchgate.net/profile/Jagat_Narula2/publication/261565592_1990-2010_Global_Cardiovascular_Disease_Atlas/links/53da2e9e0cf2631430c7fe94.pdf

  2. 2- Reddy KS. The focus of action. Global Heart. 2014; 9(1):181. Citado en PubMed; PMID: 25432127.

  3. 3- Go A, Mozaffarian D, Roger V. Heart disease and stroke statistics–2014 update: a report from the American Heart Association. Circulation. 2014;129(3):e28–292. Citado en PubMed; PMID: 24352519.

  4. 4- Smith JN, Negrelli JM, Manek MB, Hawes EM, Viera AJ.Diagnosis and Management of Acute Coronary Syndrome: An Evidence-based Update. J Am Board Fam Med. 2015;28(2):283-93. Citado en PubMed; PMID:25748771.

  5. 5- Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. Nat Rev Cardiol. 2012 Nov;9(11):620-33. Citado en PuBMed; PMID: 22922597.

  6. 6- Chow CK, Islam S, Bautista L, Rumboldt Z, Yusufali A, Xie C, et al. Parental history and myocardial infarction risk across the world: the INTERHEART study. J Am Coll Cardiol 2011;57(5):619–27. Citado en PubMed; PMID: 21272754.

  7. 7- Perk J, De BG, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J [Internet]. 2012 [citado 12 may 2015];33(13):1635–701. Disponible en: http://eurheartj.oxfordjournals.org/content/33/13/1635

  8. 8- Johnson JA, Gong L, Whirl‐Carrillo M, Gage BF, Scott SA, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clinical Pharmacology & Therapeutics [Internet]. 2011 [citado 12 May 2015];90(4): 625-9.Disponible en: http://onlinelibrary.wiley.com/doi/10.1038/clpt.2011.185/full

  9. 9- Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey DE Jr, et al. 2012 ACCF/AHA focused update of the guideline for the management of unstable angina/non-ST segment myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am CollCardiol. 2012;60(7):645–81. Citado en PubMed; PMID: 22809746.

  10. 10- Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am CollCardiol. 2014; 63(25 Pt B):2889 –934 .Citado en PubMed; PMID: 24239923.

  11. 11- Ellsworth DL, Croft DT Jr, Weyandt J, Sturtz LA, Blackburn HL, Burke A, et al. Intensive cardiovascular risk reduction induces sustainable changes in expression of genes and pathways important to vascular function. Circ Cardiovasc Genet. 2014;10:1161-21. Citado enPubMed; PMID: 24563419.

  12. 12- Hastie CE, Jeemon P, Coleman H, McCallum L, Patel R, Dawson J, et al. Long-term and ultra long-term blood pressure variability during follow-up and mortality in 14 522 patients with hypertension. Hypertension. 2013;62(4):698–705. Citado en PubMed: PMID; 23959561.

  13. 13- Williamson C, Jeemon P, Hastie CE, McCallum L, Muir S, Dawson J. et al. Blood Pressure Control and Long-term Mortality Outcomes in Hypertensive Patients. Eur Heart J. 2014;35(9):563-70. Citado en PubMed; PMID: 24344191.

  14. 14- Berry JD, Dyer A, Cai X, Garside DB, Ning H, Thomas A, et al. Lifetime risks of cardiovascular disease. N Engl J Med. 2012;366(4):321–9. Citado en PubMed; PMID: 22276822.

  15. 15- Bachmann JM, Willis BL, Ayers CR, Khera A, Berry JD. Association between family history and coronary heart disease death across long-term follow-up in men: the Cooper Center Longitudinal Study. Circulation. 2012;125(25):3092–8. Citado en PubMed; PMID: 22623718.

  16. 16- De Jongh B, Birkeland K, Brenner M. Managing Comorbidities in Patients With Chronic Heart Failure. Am J Cardiovasc Drugs. 2015;15(3):171-84. Citado en PubMed ; PMID:25837622.

  17. 17- Newby K, Marber MS, Melloni CH, Sarov Blat L, Aberle L, Aylward PE, et al. Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial. Lancet [Internet]. 2014 [citado 12 May 2015];384(9949): 1187–95. Disponible en: http://www.sciencedirect.com/science/article/pii/S0140673614604177

  18. 18- Saaby L, Poulsen TS, Diederichsen AC, Hosbond S, Larsen TB, Schmidt H, et al. Mortality rate in type 2 myocardial infarction: observations from an unselected hospital cohort. Am J Med. 2014;127(4):295–302. Citado en PubMed; PMID: 24457000.

  19. 19- Non-communicable diseases: 2015 to 2025. The Lancet [Internet].2013 [citado 12 May 2015];381(9866):509-10. Disponible en: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2813%2960100-2/fulltext

  20. 20- Baron T, Hambraeus K, Sundstrom J, Erlinge D, Jernberg T, Lindahl B, et al. Type 2 myocardial infarction in clinical practice. Heart. 2015;101(2):101–6. Citado en PuBMed; PMID: 25331532.

  21. 21- Amsterdam EA, Wenger NK, Brindis RG, Casey Jr DE, Ganiats TG, Holmes Jr DR, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Malling RW, Zieman SJ. 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes: Executive Summary. Journal of the American College of Cardiology [Internet]. 2014 [citado 12 May 2015]. Disponible en: http://content.onlinejacc.org/pdfAccess.ashx?url=/data/Journals/JAC/0/ on 10/09/2014

  22. 22- Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. NEngl J Med 2006;354:1264–72.

  23. 23- Sivapalaratnam S, Boekholdt SM, Trip MD, Sandhu MS, Luben R, Kastelein JJ, et al. Family history of premature coronary heart disease and risk prediction in the EPIC-Norfolk prospective population study. Heart. 2010;96:1985–9.

  24. 24- Michos ED, Vasamreddy CR, Becker DM, YanekLR, Moy TF, Fishman EK, Becker LC, et al. Womenwith a low Framingham risk score and a family history of premature coronary heart disease have a high prevalence of subclinical coronary atherosclerosis. Am Heart J. 2005;150:1276–81.

  25. 25-Niinikoski H, Jula A, Viikari J, Ronnemaa T, Heino P, Lagstrom H, et al. Blood pressure is lower in children and adolescents with a low-saturated-fat diet since infancy: the special Turku coronary risk factor intervention project. Hypertension. 2009;53:918–24.

  26. 26- Shaw JG, Dent AG, Passmore LH. Genetic influences on right ventricular systolic pressure (RVSP) in chronic obstructive pulmonary disease (COPD). BMC Pulm. Med. 2012:12-25.

  27. 27- Mega JL, Simon T, Collet JP. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010;304:1821-30.

  28. 28- Gurbel PA, Erlinge D, Ohman EM. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: The TRILOGY ACS platelet function substudy. JAMA. 2012;308:1785-94.

  29. 29- Abbate A, Van Tassell BW, Biondi Zoccai G .Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. Am J Cardiol. 2013;111: 1394–400.

  30. 30- Morton AC, Rothman AMK, Greenwood JP. The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA heart study. EurHeart J. 2015;36:377–84.

  31. 31- Van Schie RM, El Khedr N, Verhoef TI,Teichert M, Stricker BH, et al. Validation of the acenocoumarol EU-PACT algorithms: similar performance in the Rotterdam Study cohort as in the original study. Pharmacogenomics. 2012;13(11):1239-45.

  32. 32- French B, Joo J, Geller NL, Kimmel SE, Rosenberg Y, Anderson JL., et al. Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Trials. 2010;11(1):108.

  33. 33- Kimmel SE, French B, Kasner SB. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013;369:2283-93.

  34. 34- Pirmohamed M, Burnside G, Eriksson N. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. 2013;369:2294-303.

  35. 35- SEARCH Collaborative Group, Link E, Parish S. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med. 2008;359:789-99.

  36. 36- Sacchi AE, Olivares L, Leiro V. Xantomatosis y dislipoproteinemias. Dermatología Argentina [Internet]. 2013 [citado 12 May 2015];19(3): 174-182 Disponible en: http://www.dermatolarg.org.ar/index.php/dermatolarg/article/viewArticle/1201

  37. 37- Matías Pérez D, Pérez Campos E, García Montalvo IA. Una visión genética de la hipercolesterolemia familiar. Nutr Hosp [Internet]. 2015 [citado 12 May 2015];32(6):2421-2426. Disponible: http://www.aulamedica.es/gdcr/index.php/nh/article/view/9885/pdf_8627

  38. 38- Abbate, A and Dinarello, CA. Anti-inflammatory therapies in acute coronary syndromes: is IL-1 blockade a solution?.EurHeart J. 2014; 36:337–9.

  39. 39- Mosca L, Mochari H, Liao M, Christian AH, Edelman DJ, Aggarwal B, et al. Anovel family-based intervention trial to improve heart health: FIT Heart: results of a randomized controlled trial. Circ CardiovascQual Outcomes. 2008;1:98–106.

  40. 40- Wood DA, Kotseva K, Connolly S, Jennings C, Mead A, Jones J, et al. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial. Lancet 2008;371:1999–2012.

  41. 41- Abbate A, Dinarello CA. Anti-inflammatory therapies in acute coronary syndromes: is IL-1 blockade a solution? EurHeart J. 2014;36:337–9.

  42. 42- Molmen Hansen HE, Stolen T, Tjonna AE, Aamot IL, Ekeberg IS, Tyldum GA, et al. Aerobic interval training reduces blood pressure and improves myocardial function in hypertensive patients. Eur J PrevCardiol. 2012;19:151–60.

  43. 43- Hu G, Jousilahti P, Antikainen R, Tuomilehto J. Occupational, commuting, and leisure-time physical activity in relation to cardiovascular mortality among Finnish subjects with hypertension. Am J Hypertens2007;20:1242–50.

  44. 44- Mackay DF, Haw S, Pell JP. Impact of Scottish smoke-free legislation on smoking quit attempts and prevalence. PLoSOne. 2011;6:e26188.




2020     |     www.medigraphic.com